Wierda WG - Search Results

1

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators. Wierda WG, et al. J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194866 Free PMC article. Clinical Trial.

2

Chronic lymphocytic leukemia.

Wierda WG, Kipps TJ. Wierda WG, et al. Curr Opin Hematol. 1999 Jul;6(4):253-61. doi: 10.1097/00062752-199907000-00010. Curr Opin Hematol. 1999. PMID: 10400375 Review.

3

CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes.

Chu P, Wierda WG, Kipps TJ. Chu P, et al. Among authors: wierda wg. Blood. 2000 Jun 15;95(12):3853-8. Blood. 2000. PMID: 10845920 Free article.

4

Gene therapy of hematologic malignancies.

Wierda WG, Kipps TJ. Wierda WG, et al. Semin Oncol. 2000 Oct;27(5):502-11. Semin Oncol. 2000. PMID: 11049018 Review.

5

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. Wierda WG, et al. Blood. 2000 Nov 1;96(9):2917-24. Blood. 2000. PMID: 11049967 Free article. Clinical Trial.

6

Immunogenetic therapy for B-cell malignancies.

Kipps TJ, Chu P, Wierda WG. Kipps TJ, et al. Among authors: wierda wg. Semin Oncol. 2000 Dec;27(6 Suppl 12):104-9. Semin Oncol. 2000. PMID: 11225994 Review.

7

Immunotherapy of chronic lymphocytic leukemia.

Wierda WG, O'Brien S. Wierda WG, et al. Expert Rev Anticancer Ther. 2001 Jun;1(1):73-83. doi: 10.1586/14737140.1.1.73. Expert Rev Anticancer Ther. 2001. PMID: 12113136 Review.

8

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.

9

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Faderl S, et al. Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9. Blood. 2003. PMID: 12522009 Free article. Clinical Trial.

10

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Cortes JE, et al. Blood. 2003 May 15;101(10):3794-800. doi: 10.1182/blood-2002-09-2790. Epub 2003 Jan 30. Blood. 2003. PMID: 12560227 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

539 results

Search Page

Filters